Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial

Keyphrases

• Pediatric 100%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 100%
• Individualized Dosing 100%
• Antithymocyte Globulin 100%
• Phase II Clinical Trial 100%
• Parachute 100%
• Immune Reconstitution 87%
• CD4+ 75%
• Graft-versus-host Disease (GvHD) 50%
• Graft Failure 50%
• Hematopoietic Stem Cell Transplantation 25%
• Utrecht 25%
• Stem Cell Source 25%
• Fatal Accidents 25%
• Pediatric Oncology 12%
• Adverse Events 12%
• Netherlands 12%
• Dutch 12%
• Overall Survival 12%
• Bone Marrow 12%
• Cord Blood 12%
• Transplantation 12%
• Princess 12%
• Pediatric Patients 12%
• T Cells 12%
• Pharmacokinetics 12%
• First Dose 12%
• Improved Outcomes 12%
• 18 Years Old 12%
• Cumulative Dose 12%
• Common Terminology Criteria for Adverse Events (CTCAE) 12%
• Overexposure 12%
• CD4+ T 12%
• CD4+ T Cells 12%
• University Medical Centre 12%
• Survival Analysis 12%
• Karnofsky Performance Status 12%
• Absolute Lymphocyte Count 12%
• Dose-ranging 12%
• Immunological Disorders 12%
• Sanofi 12%

Immunology and Microbiology

• Allogeneic Hematopoietic Stem Cell Transplantation 100%
• Anti-Thymocyte Globulin 100%
• Arm 100%
• Immune Reconstitution 87%
• CD4 75%
• Graft-Versus-Host Disease 50%
• Hematopoietic Stem Cell Transplantation 25%
• Stem Cell 25%
• T-Helper Cell 25%
• T Cell 12%
• Overall Survival 12%
• Pharmacokinetics 12%
• Lymphocyte Count 12%
• Conditioning 12%
• Nomenclature 12%
• Immune System Disorders 12%